Abstract: The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. of cancers expressing the gastrin releasing peptide receptor (GRPR). For example, such probes may be molecules conjugated to detectable labels which are preferably moieties suitable for detection by gamma imaging and SPECT or by positron emission tomography (PET) or magnetic resonance imaging (MRI) or fluorescence spectroscopy or optical imaging methods.
Type:
Grant
Filed:
September 25, 2013
Date of Patent:
December 12, 2017
Assignee:
Advanced Accelerator Applications USA, Inc.
Inventors:
Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
Abstract: Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog or ortolog are described; these compounds are able to bind to the VEGF receptors and to modulate the angiogenesis mediated by the VEG.
Type:
Grant
Filed:
April 22, 2014
Date of Patent:
August 22, 2017
Assignee:
Advanced Accelerator Applications S.A.
Inventors:
Luca Domenico D'Andrea, Carlo Pedone, Maria Caterina Turco
Abstract: Nucleophile-reactive sulfonated compounds used as precursors to (radio)labelled (bio)molecules are produced by pre-introduction of a nucleophilic compound R* through an unusual nucleophile-induced ring-opening reaction of the sultone moiety of the precursor. The precursors and compounds conform to respective formulae (Ip) and (I): Also disclosed are methods for producing these precursors and compounds, as well as for conjugation of these compounds with (bio)molecules, and to the drugs obtained by this method.
Type:
Application
Filed:
February 16, 2017
Publication date:
June 8, 2017
Applicant:
Advanced Accelerator Applications SA
Inventors:
Thomas PRIEM, Cedric BOUTEILLER, Davide CAMPORESE, Anthony ROMIEU, Pierre-Yves RENARD
Abstract: Nucleophile-reactive sulfonated compounds used as precursors to (radio)labelled (bio)molecules are produced by pre-introduction of a nucleophilic compound R* through an unusual nucleophile-induced ring-opening reaction of the sultone moiety of the precursor. The precursors and compounds conform to respective formulae (Ip) and (I): Also disclosed are methods for producing these precursors and compounds, as well as for conjugation of these compounds with (bio)molecules, and to the drugs obtained by this method.
Type:
Grant
Filed:
November 22, 2013
Date of Patent:
April 4, 2017
Assignee:
Advanced Accelerator Applications SA
Inventors:
Thomas Priem, Cedric Bouteiller, Davide Camporese, Anthony Romieu, Pierre-Yves Renard
Abstract: A process for the preparation of complexes containing 68Ga wherein a buffer formic acid/formate in the presence of compounds capable to sequester metal cations is used in the complexion reaction.
Type:
Grant
Filed:
August 10, 2012
Date of Patent:
June 28, 2016
Assignee:
Advanced Accelerator Applications S.A.
Inventors:
Lorenza Fugazza, Maria Azzurra Filannino, Maurizio Franco Mariani
Abstract: The present invention is related to new peptide antagonists of ?v?3 receptor, designed on the basis of the crystal structure of integrin ?v?3 in complex with c(RGDf[NMe]V) and the NMR structure of echistatin. These peptides are potent and selective antagonists of the ?v?3 receptor and can be used as novel anticancer drugs and/or new class of diagnostic non-invasive tracers as suitable tools for ?v?3-targeted therapy and imaging.
Type:
Grant
Filed:
August 30, 2013
Date of Patent:
April 12, 2016
Assignee:
ADVANCED ACCELERATOR APPLICATIONS
Inventors:
Annarita Del Gatto, Laura Zaccaro, Carlo Pedone, Michele Saviano
Abstract: Nucleophile-reactive sulfonated compounds used as precursors to (radio)labelled (bio)molecules are produced by pre-introduction of a nucleophilic compound R* through an unusual nucleophile-induced ring-opening reaction of the sultone moiety of the precursor. The precursors and compounds conform to respective formulae (Ip) and (I): Also disclosed are methods for producing these precursors and compounds, as well as for conjugation of these compounds with (bio)molecules, and to the drugs obtained by this method.
Type:
Application
Filed:
November 22, 2013
Publication date:
October 8, 2015
Applicant:
ADVANCED ACCELERATOR APPLICATIONS SA
Inventors:
Thomas Priem, Cedric Bouteiller, Davide Camporese, Anthony Romieu, Pierre-Yves Renard
Abstract: The invention relates to polysultone derivatives used as precursors to radiolabelled macromolecules usable for medicine and in nuclear imaging. The aim of the invention is to provide novel prosthetic compounds or groupings, the synthesis of which is straightforward, easy and automatable, enabling access to economical and effective radiolabelled macromolecules. The aim is achieved by the invention, which involves compounds of formula 10 or 11. Said double-sultone derivatives are produced by opening the sultone rings using a nucleophile radical Ri which may be a radionucleide R* for one of the sultone rings and an active radical peptide Ra for the other sultone ring. The invention also relates to the method for producing the abovementioned compounds, as well as to the drugs or diagnosis products that the latter are capable of forming.
Abstract: This invention concerns the use of MicroRNA-199b-5p in medical and diagnostic fields. Particularly, this invention concerns the use of the miR199b-5p in the anti-cancer therapy and as a histophatological and metastasis marker.
Abstract: Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog or ortolog are described; these compounds are able to bind to the VEGF receptors and to modulate the angiogenesis mediated by the VEG.
Type:
Grant
Filed:
July 23, 2010
Date of Patent:
June 3, 2014
Assignee:
Advanced Accelerator Applications S.A.
Inventors:
Luca Domenico D'Andrea, Carlo Pedone, Maria Caterina Turco
Abstract: The present invention is related to new peptide antagonists of ?v?3 receptor, designed on the basis of the crystal structure of integrin ?v?3 in complex with c(RGDf[NMe]V) and the NMR structure of echistatin. These peptides are potent and selective antagonists of the ?v?3 receptor and can be used as novel anticancer drugs and/or new class of diagnostic non-invasive tracers as suitable tools for ?v?3-targeted therapy and imaging.
Type:
Application
Filed:
August 30, 2013
Publication date:
April 3, 2014
Applicant:
Advanced Accelerator Applications
Inventors:
Annarita DEL GATTO, Laura ZACCARO, Carlo PEDONE, Michele SAVIANO
Abstract: The present invention is related to new peptide antagonists of ?v?3 receptor, designed on the basis of the crystal structure of integrin ?v?3 in complex with c(RGDf[NMe]V) and the NMR structure of echistatin. These peptides are potent and selective antagonists of the ?v?3 receptor and can be used as novel anticancer drugs and/or new class of diagnostic non-invasive tracers as suitable tools for ?v?3-targeted therapy and imaging.
Type:
Grant
Filed:
October 9, 2006
Date of Patent:
October 1, 2013
Assignee:
Advanced Accelerator Applications
Inventors:
Annarita del Gatto, Laura Zaccaro, Carlo Pedone, Michele Saviano
Abstract: The use of a peptide is described as a carrier for the transport of molecules or radioisotopes into cancer cells; also described are modifications of said peptide and their use.
Abstract: Antibody or fragment thereof, which specifically binds to folate receptor-alpha (FR?), wherein said antibody or fragment thereof comprises a light chain whose variable region comprises at least one of the following amino acid sequences: —RASESVSFLGINLIH (SEQ ID NO: 3), —QASNKDT (SEQ ID NO: 4), —LQSKNFPPYT (SEQ ID NO: 5), and wherein the constant region of said light chain is a kappa constant region.
Type:
Grant
Filed:
September 12, 2007
Date of Patent:
March 5, 2013
Assignees:
Advanced Accelerator Applications S.A., Istituto Nazionale per Lo Studio E la Cura Dei Tumori
Inventors:
Franck Martin, Margherita Cattozzo, Giovanni Maurizi, Vito Di Cioccio, Mariangela Figini, Silvana Canevari
Abstract: The present invention relates to a method of producing a recombinant protein comprising using a selection method other than antibiotics. In particular, it relates to a stable host/vector system based on the pyrC gene complementation designed to produce high level of heterologous recombinant protein in Escherichia coli. The expression system of the present invention allows rapid selection of plasmid containing cells during the cloning phases and lead to high protein expression during fermentation. This system has a strong selective efficiency, especially during the induction phase, leading to the selection of an almost homogeneous and stable plasmid bearing cell population. Moreover the productivity of the culture is to a large extent better than the one based on antibiotic resistance. This elevated vector stability combined with its high productivity fulfils the requirements for heterologous protein production in Escherichia coli to an industrial level.
Type:
Grant
Filed:
October 4, 2006
Date of Patent:
September 18, 2012
Assignee:
Advanced Accelerator Applications S.A.
Inventors:
Franck Martin, Stefano Cencioni, Antonella Colagrande, Maria Cristina Thaller, Marco Maria D'Andrea, Gian Maria Rossolini
Abstract: The invention relates to polysultone derivatives used as precursors to radiolabelled macromolecules usable for medicine and in nuclear imaging. The aim of the invention is to provide novel prosthetic compounds or groupings, the synthesis of which is straightforward, easy and automatable, enabling access to economical and effective radiolabelled macromolecules. The aim is achieved by the invention, which involves compounds of formula 10 or 11. Said double-sultone derivatives are produced by opening the sultone rings using a nucleophile radical Ri which may be a radionucleide R* for one of the sultone rings and an active radical peptide Ra for the other sultone ring. The invention also relates to the method for producing the abovementioned compounds, as well as to the drugs or diagnosis products that the latter are capable of forming.
Abstract: Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog or ortolog are described; these compounds are able to bind to the VEGF receptors and to modulate the angiogenesis mediated by the VEG.
Type:
Application
Filed:
July 23, 2010
Publication date:
May 10, 2012
Applicant:
ADVANCED ACCELERATOR APPLICATIONS S.A.
Inventors:
Luca Domenico D'Andrea, Carlo Pedone, Maria Caterina Turco
Abstract: The use of a peptide is described as a carrier for the transport of molecules or radioisotopes into cancer cells; also described are modifications of said peptide and their use.